רווח תפעולי לפני ניכוי פחת: iTeos Therapeutics, Inc. (ITOS)

The EBITDA in monetary terms demonstrates cash flow dynamics, where serves as the base value of the parameter. iTeos Therapeutics management effectively manages capital, ensuring liquidity through a deal with GSK. The environmental development vector includes the modernization of filters and laboratory energy efficiency. However, the absence of commercial products creates a dependency on advances, as operational cash flow is temporarily nonexistent.

iTeos Therapeutics (ITOS) develops advanced immunotherapies to combat oncology by blocking tumor defense mechanisms. The absolute operating profit reflects cash flow before interest and taxes, allowing for an assessment of the business model's resilience and the company's ability to maintain operational efficiency. The stability of this indicator confirms real market demand for innovation, minimizing the risks of a sharp decline in the asset's price.